Cargando…

Targeting alpha synuclein and amyloid beta by a multifunctional, brain-penetrant dopamine D2/D3 agonist D-520: Potential therapeutic application in Parkinson’s disease with dementia

A significant number of people with Parkinson’s disease (PD) develop dementia in addition to cognitive dysfunction and are diagnosed as PD with dementia (PDD). This is characterized by cortical and limbic alpha synuclein (α-syn) accumulation, and high levels of diffuse amyloid beta (Aβ) plaques in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yedlapudi, Deepthi, Xu, Liping, Luo, Dan, Marsh, Gregory B., Todi, Sokol V., Dutta, Aloke K.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927976/ https://www.ncbi.nlm.nih.gov/pubmed/31873106 http://dx.doi.org/10.1038/s41598-019-55830-3

Ejemplares similares

Inhibition of alpha-synuclein aggregation by multifunctional dopamine agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model
por: Yedlapudi, Deepthi, et al.
Publicado: (2016)

The Chaperone-Like Activity of α-Synuclein Attenuates Aggregation of Its Alternatively Spliced Isoform, 112-Synuclein In Vitro: Plausible Cross-Talk between Isoforms in Protein Aggregation
por: Manda, Krishna Madhuri, et al.
Publicado: (2014)

Pharmacological and Behavioral Characterization of D-473, an Orally Active Triple Reuptake Inhibitor Targeting Dopamine, Serotonin and Norepinephrine Transporters
por: Dutta, Aloke K., et al.
Publicado: (2014)

Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists
por: Pogorelov, Vladimir M., et al.
Publicado: (2023)

Successful treatment of dopamine dysregulation syndrome with dopamine D(2) partial agonist antipsychotic drug
por: Mizushima, Jin, et al.
Publicado: (2012)

Progressive Adaptation in Physical Activity and Neuromuscular Performance during 520d Confinement
por: Belavý, Daniel L., et al.
Publicado: (2013)

Hsa-miR-520d Converts Fibroblasts into CD105+ Populations
por: Ishihara, Yoshitaka, et al.
Publicado: (2014)

Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment
por: Isaacson, Stuart H., et al.
Publicado: (2023)

Dopamine receptor D1- and D2-agonists do not spark brown adipose tissue thermogenesis in mice
por: Raffaelli, Francesca-Maria, et al.
Publicado: (2020)

Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
por: Mandic-Maravic, Vanja, et al.
Publicado: (2022)

Novel and Potent Dopamine D(2) Receptor Go-Protein Biased Agonists
por: Bonifazi, Alessandro, et al.
Publicado: (2019)

PMON169 D2R Expression in Dopamine-Agonist Resistant Prolactinomas
por: Levine, Alice, et al.
Publicado: (2022)

Modulation of Alpha-Synuclein Aggregation by Dopamine Analogs
por: Latawiec, Diane, et al.
Publicado: (2010)

Dopamine-Induced Conformational Changes in Alpha-Synuclein
por: Outeiro, Tiago F., et al.
Publicado: (2009)

LDL Receptor Pathway Regulation by miR-224 and miR-520d
por: Salerno, Alessandro G., et al.
Publicado: (2020)

In Vitro and In Silico Characterization of Kurarinone as a Dopamine D(1A) Receptor Antagonist and D(2L) and D(4) Receptor Agonist
por: Prajapati, Ritu, et al.
Publicado: (2021)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Agonist signalling properties of radiotracers used for imaging of dopamine D(2/3) receptors
por: van Wieringen, Jan-Peter, et al.
Publicado: (2014)

Inhibitory Effects of Dopamine Receptor D(1) Agonist on Mammary Tumor and Bone Metastasis
por: Minami, Kazumasa, et al.
Publicado: (2017)

Chirality of Novel Bitopic Agonists Determines Unique Pharmacology at the Dopamine D3 Receptor
por: Adhikari, Pramisha, et al.
Publicado: (2021)

Dopamine D(1) Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease
por: Lewis, Mechelle M., et al.
Publicado: (2023)

Enhanced Taste Recognition Following Subacute Treatment With The Dopamine D2/D3 Receptor Agonist Pramipexole in Healthy Volunteers
por: Kaltenboeck, Alexander, et al.
Publicado: (2022)

Specificity of striatal dopamine D(1) system in humans: implications for clinical use of D(1) receptor-agonists in Parkinson's disease
por: Goto, Satoshi
Publicado: (2023)

Changes of Locomotor Activity by Dopamine D2, D3 Agonist Quinpirole in Mice Using Home-cage Monitoring System
por: Park, Jeonghyun, et al.
Publicado: (2023)

Dopamine, Alpha-Synuclein, and Mitochondrial Dysfunctions in Parkinsonian Eyes
por: Indrieri, Alessia, et al.
Publicado: (2020)

Dopamine D2 Long Receptors Are Critical for Caveolae-Mediated α-Synuclein Uptake in Cultured Dopaminergic Neurons
por: Kawahata, Ichiro, et al.
Publicado: (2021)

Chronic exposure to dopamine agonists affects the integrity of striatal D(2) receptors in Parkinson's patients
por: Politis, Marios, et al.
Publicado: (2017)

Discovery research and development history of the dopamine D(2) receptor partial agonists, aripiprazole and brexpiprazole
por: Kikuchi, Tetsuro, et al.
Publicado: (2021)

Dopamine D(2) Receptor Agonist Binding Kinetics—Role of a Conserved Serine Residue
por: Ågren, Richard, et al.
Publicado: (2021)

Cariprazine, A Dopamine D(2)/D(3) Receptor Partial Agonist, Modulates ABCG2-Mediated Multidrug Resistance in Cancer
por: Hussein, Noor, et al.
Publicado: (2018)

Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated
por: Sohur, U. Shivraj, et al.
Publicado: (2018)

The Role of the Dopamine D2 Receptor in Form-Deprivation Myopia in Mice: Studies With Full and Partial D2 Receptor Agonists and Knockouts
por: Huang, Furong, et al.
Publicado: (2020)

Pramipexole, a dopamine D3/D2 receptor-preferring agonist, attenuates reserpine-induced fibromyalgia-like model in mice
por: Martins, Carlos Pereira, et al.
Publicado: (2021)

Alpha-synuclein is strategically positioned for afferent modulation of midbrain dopamine neurons and is essential for cocaine preference
por: Trubetckaia, Olga, et al.
Publicado: (2019)

Binding of Dopamine to Alpha-Synuclein is Mediated by Specific Conformational States
por: Illes-Toth, Eva, et al.
Publicado: (2013)

Examining the mechanisms that link β-amyloid and α-synuclein pathologies
por: Marsh, Samuel E, et al.
Publicado: (2012)

Conscious perception and the modulatory role of dopamine: no effect of the dopamine D2 agonist cabergoline on visual masking, the attentional blink, and probabilistic discrimination
por: Boonstra, E.A, et al.
Publicado: (2020)

Identification of the Beer Component Hordenine as Food-Derived Dopamine D2 Receptor Agonist by Virtual Screening a 3D Compound Database
por: Sommer, Thomas, et al.
Publicado: (2017)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Fluorescent ligands for dopamine D(2)/D(3) receptors
por: Allikalt, Anni, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6ada0h20sagsi2le7108k224vf